Ontology highlight
ABSTRACT: Introduction
Diffuse large B-cell lymphoma (DLBCL) is genetically and clinically heterogeneous. Despite advances in genomic subtyping, standard frontline chemoimmunotherapy has remained unchanged for years. As high-throughput analysis becomes more accessible, characterizing drug-gene interactions in DLBCL could support patient-specific treatment strategies.Materials and methods
From our systematic literature review, we compiled a comprehensive list of somatic mutations implicated in DLBCL. We extracted reported and primary sequencing data for these mutations and assessed their association with signaling pathways, cell-of-origin subtypes, and clinical outcomes.Results
Twenty-two targetable mutations present in ≥ 5% of patients with DLBCL were associated with unfavora
SUBMITTER: Patel SP
PROVIDER: S-EPMC7136133 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature